NCT05278546View on ClinicalTrials.gov

A Study of ILB2109 in Patients With Advanced Solid Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

February 28, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

ILB2109

ILB2109 tablets by mouth once per day at dosages prespecified by the protocol. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

Trial Locations (2)

25117

Shandong Cancer Hospital and Institute, Jinan

200123

Shanghai East Hospital, Shanghai

Sponsors

Lead Sponsor

Innolake Biopharm
All Listed Sponsors
collaborator

Shanghai East Hospital

OTHER

collaborator

Shandong Cancer Hospital and Institute

OTHER

lead

Innolake Biopharm

INDUSTRY